Company Filing History:
Years Active: 2016
Title: The Innovations of Jeffrey A. Torestsky
Introduction
Jeffrey A. Torestsky is an accomplished inventor based in Silver Spring, MD. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target cancer cells. His innovative work has led to the creation of a patent that holds promise for cancer treatment.
Latest Patents
Torestsky's most notable patent is focused on Ezrin inhibitors and methods of making and using them. This invention encompasses a compound and pharmaceutical composition that includes a specific formula, which is useful for inhibiting the ezrin protein in a cell. The patent also addresses the inhibition of cancer cell growth, showcasing Torestsky's commitment to advancing medical science.
Career Highlights
Jeffrey A. Torestsky is affiliated with Georgetown University, where he continues to engage in research and development. His work at the university allows him to collaborate with other experts in the field, further enhancing his contributions to innovation in pharmaceuticals.
Collaborations
Torestsky has worked alongside notable colleagues, including Milton L. Brown and Mikell Paige. These collaborations have enriched his research and have been instrumental in the development of his patented inventions.
Conclusion
Jeffrey A. Torestsky's innovative work in developing Ezrin inhibitors represents a significant advancement in cancer treatment. His contributions to the field of pharmaceuticals highlight the importance of research and collaboration in driving medical innovation.
Inventor’s Patent Attorneys refers to legal professionals with specialized expertise in representing inventors throughout the patent process. These attorneys assist inventors in navigating the complexities of patent law, including filing patent applications, conducting patent searches, and protecting intellectual property rights. They play a crucial role in helping inventors secure patents for their innovative creations.